APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drug Contaminants Detection and Analysis

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Contaminants Detection and Analysis Market Outlook and Growth Opportunities 2026

Report ID 17412309044 June 2026210 pages

Choose your research edition.

Industry ResearchDrug Contaminants Detection and Analysis Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Contaminants Detection and Analysis Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Drug Contaminants Detection and Analysis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Contaminants Detection and Analysis Market Outlook and Growth Opportunities 2026210 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Contaminants Detection and Analysis Market Analysis and Forecast 2026-2032250 pages · $4,950 USD

Market perspective

The global Drug Contaminants Detection and Analysis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Contaminants Detection and Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Contaminants Detection and Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Contaminants Detection and Analysis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Contaminants Detection and Analysis market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Contaminants Detection and Analysis market include Eurofins Scientific (Luxembourg), SGS (Switzerland), Intertek (UK), Thermo Fisher Scientific (USA), Charles River Laboratories (USA), Labcorp Biopharma (USA), WuXi STA / WuXi AppTec (China), Cambrex (USA) and Pharmaron (China), among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Contaminants Detection and Analysis market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Contaminants Detection and Analysis and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Contaminants Detection and Analysis revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Contaminants Detection and Analysis market.

Drug Contaminants Detection and Analysis Segment by Company

Eurofins Scientific (Luxembourg)

SGS (Switzerland)

Intertek (UK)

Thermo Fisher Scientific (USA)

Charles River Laboratories (USA)

Labcorp Biopharma (USA)

WuXi STA / WuXi AppTec (China)

Cambrex (USA)

Pharmaron (China)

Piramal Pharma Solutions (India)

Syngene (India)

Recipharm (Sweden)

Almac Sciences (UK)

MedPharm (UK)

CMIC (Japan)

Aenova (Germany)

Sterling Pharma Solutions (UK)

Curia (USA)

Ardena (Belgium)

Hovione (Portugal)

Delpharm (France)

AGC Biologics (USA)

FUJIFILM Biotechnologies (Japan)

KBI Biopharma (USA)

Rentschler Biopharma (Germany)

Ajinomoto Bio-Pharma Services (Japan)

Bora Pharmaceuticals (Taiwan, China)

Kindeva (USA)

CordenPharma (Switzerland)

RSSL (UK)

Tentamus (Germany)

Element Materials Technology (UK)

Nucro-Technics (Canada)

ALS (Australia)

Aizant (India)

Wickham Laboratories (UK)

Toxikon (USA)

Evotec (Germany)

Drug Contaminants Detection and Analysis Segment by Type

Organic Pollutant Detection Products

Inorganic Pollutant Detection Products

Others

Drug Contaminants Detection and Analysis Segment by Application

Chemical Pharmaceutical Industry

Biopharmaceutical Industry

Traditional Chinese Medicine and Natural Medicine Industry

Others

Drug Contaminants Detection and Analysis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Contaminants Detection and Analysis status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Contaminants Detection and Analysis key companies, revenue, market share, and recent developments.

3. To split the Drug Contaminants Detection and Analysis breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Contaminants Detection and Analysis market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Contaminants Detection and Analysis significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Contaminants Detection and Analysis competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Contaminants Detection and Analysis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Contaminants Detection and Analysis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Contaminants Detection and Analysis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Contaminants Detection and Analysis industry.

Chapter 3: Detailed analysis of Drug Contaminants Detection and Analysis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Contaminants Detection and Analysis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Contaminants Detection and Analysis in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Contaminants Detection and Analysis Industry Trends Table 2. Drug Contaminants Detection and Analysis Industry Drivers Table 3. Drug Contaminants Detection and Analysis Industry Opportunities and Challenges Table 4. Drug Contaminants Detection and Analysis Industry Restraints Table 5. Global Drug Contaminants Detection and Analysis Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Contaminants Detection and Analysis Revenue Share by Company (2021-2026) Table 7. Global Drug Contaminants Detection and Analysis Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Contaminants Detection and Analysis Key Company Manufacturing Base & Headquarters Table 9. Global Drug Contaminants Detection and Analysis Company, Product Type & Application Table 10. Global Drug Contaminants Detection and Analysis Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Contaminants Detection and Analysis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Organic Pollutant Detection Products Table 15. Significant Companies of Inorganic Pollutant Detection Products Table 16. Significant Companies of Others Table 17. Global Drug Contaminants Detection and Analysis Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Drug Contaminants Detection and Analysis Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Drug Contaminants Detection and Analysis Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Drug Contaminants Detection and Analysis Sales Value Share by Type (2021-2026) Table 21. Global Drug Contaminants Detection and Analysis Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Chemical Pharmaceutical Industry Table 23. Significant Companies of Biopharmaceutical Industry Table 24. Significant Companies of Traditional Chinese Medicine and Natural Medicine Industry Table 25. Significant Companies of Others Table 26. Global Drug Contaminants Detection and Analysis Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Contaminants Detection and Analysis Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Drug Contaminants Detection and Analysis Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Drug Contaminants Detection and Analysis Sales Value Share by Application (2021-2026) Table 30. Global Drug Contaminants Detection and Analysis Sales Value Share by Application (2027-2032) Table 31. Global Drug Contaminants Detection and Analysis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Contaminants Detection and Analysis Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Drug Contaminants Detection and Analysis Sales Value Share by Region (2021-2026) Table 34. Global Drug Contaminants Detection and Analysis Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Drug Contaminants Detection and Analysis Sales Value Share by Region (2027-2032) Table 36. Global Drug Contaminants Detection and Analysis Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Drug Contaminants Detection and Analysis Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Drug Contaminants Detection and Analysis Sales Value Market Share by Country (2021-2026) Table 39. Global Drug Contaminants Detection and Analysis Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Drug Contaminants Detection and Analysis Sales Value Market Share by Country (2027-2032) Table 41. Eurofins Scientific (Luxembourg) Company Information Table 42. Eurofins Scientific (Luxembourg) Business Overview Table 43. Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Product Portfolio Table 45. Eurofins Scientific (Luxembourg) Recent Development Table 46. SGS (Switzerland) Company Information Table 47. SGS (Switzerland) Business Overview Table 48. SGS (Switzerland) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. SGS (Switzerland) Drug Contaminants Detection and Analysis Product Portfolio Table 50. SGS (Switzerland) Recent Development Table 51. Intertek (UK) Company Information Table 52. Intertek (UK) Business Overview Table 53. Intertek (UK) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Intertek (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 55. Intertek (UK) Recent Development Table 56. Thermo Fisher Scientific (USA) Company Information Table 57. Thermo Fisher Scientific (USA) Business Overview Table 58. Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 60. Thermo Fisher Scientific (USA) Recent Development Table 61. Charles River Laboratories (USA) Company Information Table 62. Charles River Laboratories (USA) Business Overview Table 63. Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 65. Charles River Laboratories (USA) Recent Development Table 66. Labcorp Biopharma (USA) Company Information Table 67. Labcorp Biopharma (USA) Business Overview Table 68. Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 70. Labcorp Biopharma (USA) Recent Development Table 71. WuXi STA / WuXi AppTec (China) Company Information Table 72. WuXi STA / WuXi AppTec (China) Business Overview Table 73. WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Product Portfolio Table 75. WuXi STA / WuXi AppTec (China) Recent Development Table 76. Cambrex (USA) Company Information Table 77. Cambrex (USA) Business Overview Table 78. Cambrex (USA) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Cambrex (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 80. Cambrex (USA) Recent Development Table 81. Pharmaron (China) Company Information Table 82. Pharmaron (China) Business Overview Table 83. Pharmaron (China) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pharmaron (China) Drug Contaminants Detection and Analysis Product Portfolio Table 85. Pharmaron (China) Recent Development Table 86. Piramal Pharma Solutions (India) Company Information Table 87. Piramal Pharma Solutions (India) Business Overview Table 88. Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Product Portfolio Table 90. Piramal Pharma Solutions (India) Recent Development Table 91. Syngene (India) Company Information Table 92. Syngene (India) Business Overview Table 93. Syngene (India) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Syngene (India) Drug Contaminants Detection and Analysis Product Portfolio Table 95. Syngene (India) Recent Development Table 96. Recipharm (Sweden) Company Information Table 97. Recipharm (Sweden) Business Overview Table 98. Recipharm (Sweden) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Recipharm (Sweden) Drug Contaminants Detection and Analysis Product Portfolio Table 100. Recipharm (Sweden) Recent Development Table 101. Almac Sciences (UK) Company Information Table 102. Almac Sciences (UK) Business Overview Table 103. Almac Sciences (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Almac Sciences (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 105. Almac Sciences (UK) Recent Development Table 106. MedPharm (UK) Company Information Table 107. MedPharm (UK) Business Overview Table 108. MedPharm (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. MedPharm (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 110. MedPharm (UK) Recent Development Table 111. CMIC (Japan) Company Information Table 112. CMIC (Japan) Business Overview Table 113. CMIC (Japan) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. CMIC (Japan) Drug Contaminants Detection and Analysis Product Portfolio Table 115. CMIC (Japan) Recent Development Table 116. Aenova (Germany) Company Information Table 117. Aenova (Germany) Business Overview Table 118. Aenova (Germany) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Aenova (Germany) Drug Contaminants Detection and Analysis Product Portfolio Table 120. Aenova (Germany) Recent Development Table 121. Sterling Pharma Solutions (UK) Company Information Table 122. Sterling Pharma Solutions (UK) Business Overview Table 123. Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 125. Sterling Pharma Solutions (UK) Recent Development Table 126. Curia (USA) Company Information Table 127. Curia (USA) Business Overview Table 128. Curia (USA) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Curia (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 130. Curia (USA) Recent Development Table 131. Ardena (Belgium) Company Information Table 132. Ardena (Belgium) Business Overview Table 133. Ardena (Belgium) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Ardena (Belgium) Drug Contaminants Detection and Analysis Product Portfolio Table 135. Ardena (Belgium) Recent Development Table 136. Hovione (Portugal) Company Information Table 137. Hovione (Portugal) Business Overview Table 138. Hovione (Portugal) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Hovione (Portugal) Drug Contaminants Detection and Analysis Product Portfolio Table 140. Hovione (Portugal) Recent Development Table 141. Delpharm (France) Company Information Table 142. Delpharm (France) Business Overview Table 143. Delpharm (France) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Delpharm (France) Drug Contaminants Detection and Analysis Product Portfolio Table 145. Delpharm (France) Recent Development Table 146. AGC Biologics (USA) Company Information Table 147. AGC Biologics (USA) Business Overview Table 148. AGC Biologics (USA) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. AGC Biologics (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 150. AGC Biologics (USA) Recent Development Table 151. FUJIFILM Biotechnologies (Japan) Company Information Table 152. FUJIFILM Biotechnologies (Japan) Business Overview Table 153. FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Product Portfolio Table 155. FUJIFILM Biotechnologies (Japan) Recent Development Table 156. KBI Biopharma (USA) Company Information Table 157. KBI Biopharma (USA) Business Overview Table 158. KBI Biopharma (USA) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. KBI Biopharma (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 160. KBI Biopharma (USA) Recent Development Table 161. Rentschler Biopharma (Germany) Company Information Table 162. Rentschler Biopharma (Germany) Business Overview Table 163. Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Product Portfolio Table 165. Rentschler Biopharma (Germany) Recent Development Table 166. Ajinomoto Bio-Pharma Services (Japan) Company Information Table 167. Ajinomoto Bio-Pharma Services (Japan) Business Overview Table 168. Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Product Portfolio Table 170. Ajinomoto Bio-Pharma Services (Japan) Recent Development Table 171. Bora Pharmaceuticals (Taiwan, China) Company Information Table 172. Bora Pharmaceuticals (Taiwan, China) Business Overview Table 173. Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 174. Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Product Portfolio Table 175. Bora Pharmaceuticals (Taiwan, China) Recent Development Table 176. Kindeva (USA) Company Information Table 177. Kindeva (USA) Business Overview Table 178. Kindeva (USA) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 179. Kindeva (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 180. Kindeva (USA) Recent Development Table 181. CordenPharma (Switzerland) Company Information Table 182. CordenPharma (Switzerland) Business Overview Table 183. CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 184. CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Product Portfolio Table 185. CordenPharma (Switzerland) Recent Development Table 186. RSSL (UK) Company Information Table 187. RSSL (UK) Business Overview Table 188. RSSL (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 189. RSSL (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 190. RSSL (UK) Recent Development Table 191. Tentamus (Germany) Company Information Table 192. Tentamus (Germany) Business Overview Table 193. Tentamus (Germany) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 194. Tentamus (Germany) Drug Contaminants Detection and Analysis Product Portfolio Table 195. Tentamus (Germany) Recent Development Table 196. Element Materials Technology (UK) Company Information Table 197. Element Materials Technology (UK) Business Overview Table 198. Element Materials Technology (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 199. Element Materials Technology (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 200. Element Materials Technology (UK) Recent Development Table 201. Nucro-Technics (Canada) Company Information Table 202. Nucro-Technics (Canada) Business Overview Table 203. Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 204. Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Product Portfolio Table 205. Nucro-Technics (Canada) Recent Development Table 206. ALS (Australia) Company Information Table 207. ALS (Australia) Business Overview Table 208. ALS (Australia) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 209. ALS (Australia) Drug Contaminants Detection and Analysis Product Portfolio Table 210. ALS (Australia) Recent Development Table 211. Aizant (India) Company Information Table 212. Aizant (India) Business Overview Table 213. Aizant (India) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 214. Aizant (India) Drug Contaminants Detection and Analysis Product Portfolio Table 215. Aizant (India) Recent Development Table 216. Wickham Laboratories (UK) Company Information Table 217. Wickham Laboratories (UK) Business Overview Table 218. Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 219. Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Product Portfolio Table 220. Wickham Laboratories (UK) Recent Development Table 221. Toxikon (USA) Company Information Table 222. Toxikon (USA) Business Overview Table 223. Toxikon (USA) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 224. Toxikon (USA) Drug Contaminants Detection and Analysis Product Portfolio Table 225. Toxikon (USA) Recent Development Table 226. Evotec (Germany) Company Information Table 227. Evotec (Germany) Business Overview Table 228. Evotec (Germany) Drug Contaminants Detection and Analysis Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 229. Evotec (Germany) Drug Contaminants Detection and Analysis Product Portfolio Table 230. Evotec (Germany) Recent Development Table 231. Research Programs/Design for This Report Table 232. Authors List of This Report Table 233. Secondary Sources Table 234. Primary Sources List of Figures Figure 1. Drug Contaminants Detection and Analysis Product Image Figure 2. Global Drug Contaminants Detection and Analysis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Contaminants Detection and Analysis Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Contaminants Detection and Analysis Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Organic Pollutant Detection Products Image Figure 8. Inorganic Pollutant Detection Products Image Figure 9. Others Image Figure 10. Global Drug Contaminants Detection and Analysis Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Drug Contaminants Detection and Analysis Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Drug Contaminants Detection and Analysis Sales Value Share by Type (2021-2032) Figure 13. Chemical Pharmaceutical Industry Image Figure 14. Biopharmaceutical Industry Image Figure 15. Traditional Chinese Medicine and Natural Medicine Industry Image Figure 16. Others Image Figure 17. Global Drug Contaminants Detection and Analysis Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Contaminants Detection and Analysis Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Contaminants Detection and Analysis Sales Value Share by Application (2021-2032) Figure 20. Global Drug Contaminants Detection and Analysis Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Drug Contaminants Detection and Analysis Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Drug Contaminants Detection and Analysis Sales Value (2021-2032) & (US$ Million) Figure 23. North America Drug Contaminants Detection and Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Drug Contaminants Detection and Analysis Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Drug Contaminants Detection and Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Drug Contaminants Detection and Analysis Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Drug Contaminants Detection and Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Drug Contaminants Detection and Analysis Sales Value (2021-2032) & (US$ Million) Figure 29. South America Drug Contaminants Detection and Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Drug Contaminants Detection and Analysis Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Drug Contaminants Detection and Analysis Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Drug Contaminants Detection and Analysis Sales Value Share by App

Scope & coverage.

Types
  • Organic Pollutant Detection Products
  • Inorganic Pollutant Detection Products
  • Others
Applications
  • Chemical Pharmaceutical Industry
  • Biopharmaceutical Industry
  • Traditional Chinese Medicine and Natural Medicine Industry
  • Others
Companies covered
  • Eurofins Scientific (Luxembourg)
  • SGS (Switzerland)
  • Intertek (UK)
  • Thermo Fisher Scientific (USA)
  • Charles River Laboratories (USA)
  • Labcorp Biopharma (USA)
  • WuXi STA / WuXi AppTec (China)
  • Cambrex (USA)
  • Pharmaron (China)
  • Piramal Pharma Solutions (India)
  • Syngene (India)
  • Recipharm (Sweden)
  • Almac Sciences (UK)
  • MedPharm (UK)
  • CMIC (Japan)
  • Aenova (Germany)
  • Sterling Pharma Solutions (UK)
  • Curia (USA)
  • Ardena (Belgium)
  • Hovione (Portugal)
  • Delpharm (France)
  • AGC Biologics (USA)
  • FUJIFILM Biotechnologies (Japan)
  • KBI Biopharma (USA)
  • Rentschler Biopharma (Germany)
  • Ajinomoto Bio-Pharma Services (Japan)
  • Bora Pharmaceuticals (Taiwan, China)
  • Kindeva (USA)
  • CordenPharma (Switzerland)
  • RSSL (UK)
  • Tentamus (Germany)
  • Element Materials Technology (UK)
  • Nucro-Technics (Canada)
  • ALS (Australia)
  • Aizant (India)
  • Wickham Laboratories (UK)
  • Toxikon (USA)
  • Evotec (Germany)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Contaminants Detection and Analysis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Contaminants Detection and Analysis Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Contaminants Detection and Analysis Market Dynamics
  1. 2.1 Drug Contaminants Detection and Analysis Industry Trends
  2. 2.2 Drug Contaminants Detection and Analysis Industry Drivers
  3. 2.3 Drug Contaminants Detection and Analysis Industry Opportunities and Challenges
  4. 2.4 Drug Contaminants Detection and Analysis Industry Restraints
3 Drug Contaminants Detection and Analysis Market by Company
  1. 3.1 Global Drug Contaminants Detection and Analysis Company Revenue Ranking in 2025
  2. 3.2 Global Drug Contaminants Detection and Analysis Revenue by Company (2021-2026)
  3. 3.3 Global Drug Contaminants Detection and Analysis Company Ranking (2024-2026)
  4. 3.4 Global Drug Contaminants Detection and Analysis Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Contaminants Detection and Analysis Company Product Type and Application
  6. 3.6 Global Drug Contaminants Detection and Analysis Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Contaminants Detection and Analysis Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Contaminants Detection and Analysis Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Contaminants Detection and Analysis Market by Type
  1. 4.1 Drug Contaminants Detection and Analysis Type Introduction
  2. 4.1.1 Organic Pollutant Detection Products
  3. 4.1.2 Inorganic Pollutant Detection Products
  4. 4.1.3 Others
  5. 4.2 Global Drug Contaminants Detection and Analysis Sales Value by Type
  6. 4.2.1 Global Drug Contaminants Detection and Analysis Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Drug Contaminants Detection and Analysis Sales Value by Type (2021-2032)
  8. 4.2.3 Global Drug Contaminants Detection and Analysis Sales Value Share by Type (2021-2032)
5 Drug Contaminants Detection and Analysis Market by Application
  1. 5.1 Drug Contaminants Detection and Analysis Application Introduction
  2. 5.1.1 Chemical Pharmaceutical Industry
  3. 5.1.2 Biopharmaceutical Industry
  4. 5.1.3 Traditional Chinese Medicine and Natural Medicine Industry
  5. 5.1.4 Others
  6. 5.2 Global Drug Contaminants Detection and Analysis Sales Value by Application
  7. 5.2.1 Global Drug Contaminants Detection and Analysis Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Drug Contaminants Detection and Analysis Sales Value by Application (2021-2032)
  9. 5.2.3 Global Drug Contaminants Detection and Analysis Sales Value Share by Application (2021-2032)
6 Drug Contaminants Detection and Analysis Regional Value Analysis
  1. 6.1 Global Drug Contaminants Detection and Analysis Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Contaminants Detection and Analysis Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Contaminants Detection and Analysis Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Contaminants Detection and Analysis Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Contaminants Detection and Analysis Sales Value (2021-2032)
  7. 6.3.2 North America Drug Contaminants Detection and Analysis Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Contaminants Detection and Analysis Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Contaminants Detection and Analysis Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Contaminants Detection and Analysis Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Contaminants Detection and Analysis Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Contaminants Detection and Analysis Sales Value (2021-2032)
  16. 6.6.2 South America Drug Contaminants Detection and Analysis Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Contaminants Detection and Analysis Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Contaminants Detection and Analysis Sales Value Share by Country, 2025 VS 2032
7 Drug Contaminants Detection and Analysis Country-level Value Analysis
  1. 7.1 Global Drug Contaminants Detection and Analysis Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Contaminants Detection and Analysis Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Contaminants Detection and Analysis Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Contaminants Detection and Analysis Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Contaminants Detection and Analysis Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Contaminants Detection and Analysis Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Contaminants Detection and Analysis Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eurofins Scientific (Luxembourg)
  2. 8.1.1 Eurofins Scientific (Luxembourg) Company Information
  3. 8.1.2 Eurofins Scientific (Luxembourg) Business Overview
  4. 8.1.3 Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eurofins Scientific (Luxembourg) Drug Contaminants Detection and Analysis Product Portfolio
  6. 8.1.5 Eurofins Scientific (Luxembourg) Recent Developments
  7. 8.2 SGS (Switzerland)
  8. 8.2.1 SGS (Switzerland) Company Information
  9. 8.2.2 SGS (Switzerland) Business Overview
  10. 8.2.3 SGS (Switzerland) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  11. 8.2.4 SGS (Switzerland) Drug Contaminants Detection and Analysis Product Portfolio
  12. 8.2.5 SGS (Switzerland) Recent Developments
  13. 8.3 Intertek (UK)
  14. 8.3.1 Intertek (UK) Company Information
  15. 8.3.2 Intertek (UK) Business Overview
  16. 8.3.3 Intertek (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Intertek (UK) Drug Contaminants Detection and Analysis Product Portfolio
  18. 8.3.5 Intertek (UK) Recent Developments
  19. 8.4 Thermo Fisher Scientific (USA)
  20. 8.4.1 Thermo Fisher Scientific (USA) Company Information
  21. 8.4.2 Thermo Fisher Scientific (USA) Business Overview
  22. 8.4.3 Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Thermo Fisher Scientific (USA) Drug Contaminants Detection and Analysis Product Portfolio
  24. 8.4.5 Thermo Fisher Scientific (USA) Recent Developments
  25. 8.5 Charles River Laboratories (USA)
  26. 8.5.1 Charles River Laboratories (USA) Company Information
  27. 8.5.2 Charles River Laboratories (USA) Business Overview
  28. 8.5.3 Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Charles River Laboratories (USA) Drug Contaminants Detection and Analysis Product Portfolio
  30. 8.5.5 Charles River Laboratories (USA) Recent Developments
  31. 8.6 Labcorp Biopharma (USA)
  32. 8.6.1 Labcorp Biopharma (USA) Company Information
  33. 8.6.2 Labcorp Biopharma (USA) Business Overview
  34. 8.6.3 Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Labcorp Biopharma (USA) Drug Contaminants Detection and Analysis Product Portfolio
  36. 8.6.5 Labcorp Biopharma (USA) Recent Developments
  37. 8.7 WuXi STA / WuXi AppTec (China)
  38. 8.7.1 WuXi STA / WuXi AppTec (China) Company Information
  39. 8.7.2 WuXi STA / WuXi AppTec (China) Business Overview
  40. 8.7.3 WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  41. 8.7.4 WuXi STA / WuXi AppTec (China) Drug Contaminants Detection and Analysis Product Portfolio
  42. 8.7.5 WuXi STA / WuXi AppTec (China) Recent Developments
  43. 8.8 Cambrex (USA)
  44. 8.8.1 Cambrex (USA) Company Information
  45. 8.8.2 Cambrex (USA) Business Overview
  46. 8.8.3 Cambrex (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cambrex (USA) Drug Contaminants Detection and Analysis Product Portfolio
  48. 8.8.5 Cambrex (USA) Recent Developments
  49. 8.9 Pharmaron (China)
  50. 8.9.1 Pharmaron (China) Company Information
  51. 8.9.2 Pharmaron (China) Business Overview
  52. 8.9.3 Pharmaron (China) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pharmaron (China) Drug Contaminants Detection and Analysis Product Portfolio
  54. 8.9.5 Pharmaron (China) Recent Developments
  55. 8.10 Piramal Pharma Solutions (India)
  56. 8.10.1 Piramal Pharma Solutions (India) Company Information
  57. 8.10.2 Piramal Pharma Solutions (India) Business Overview
  58. 8.10.3 Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Piramal Pharma Solutions (India) Drug Contaminants Detection and Analysis Product Portfolio
  60. 8.10.5 Piramal Pharma Solutions (India) Recent Developments
  61. 8.11 Syngene (India)
  62. 8.11.1 Syngene (India) Company Information
  63. 8.11.2 Syngene (India) Business Overview
  64. 8.11.3 Syngene (India) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Syngene (India) Drug Contaminants Detection and Analysis Product Portfolio
  66. 8.11.5 Syngene (India) Recent Developments
  67. 8.12 Recipharm (Sweden)
  68. 8.12.1 Recipharm (Sweden) Company Information
  69. 8.12.2 Recipharm (Sweden) Business Overview
  70. 8.12.3 Recipharm (Sweden) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Recipharm (Sweden) Drug Contaminants Detection and Analysis Product Portfolio
  72. 8.12.5 Recipharm (Sweden) Recent Developments
  73. 8.13 Almac Sciences (UK)
  74. 8.13.1 Almac Sciences (UK) Company Information
  75. 8.13.2 Almac Sciences (UK) Business Overview
  76. 8.13.3 Almac Sciences (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Almac Sciences (UK) Drug Contaminants Detection and Analysis Product Portfolio
  78. 8.13.5 Almac Sciences (UK) Recent Developments
  79. 8.14 MedPharm (UK)
  80. 8.14.1 MedPharm (UK) Company Information
  81. 8.14.2 MedPharm (UK) Business Overview
  82. 8.14.3 MedPharm (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  83. 8.14.4 MedPharm (UK) Drug Contaminants Detection and Analysis Product Portfolio
  84. 8.14.5 MedPharm (UK) Recent Developments
  85. 8.15 CMIC (Japan)
  86. 8.15.1 CMIC (Japan) Company Information
  87. 8.15.2 CMIC (Japan) Business Overview
  88. 8.15.3 CMIC (Japan) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  89. 8.15.4 CMIC (Japan) Drug Contaminants Detection and Analysis Product Portfolio
  90. 8.15.5 CMIC (Japan) Recent Developments
  91. 8.16 Aenova (Germany)
  92. 8.16.1 Aenova (Germany) Company Information
  93. 8.16.2 Aenova (Germany) Business Overview
  94. 8.16.3 Aenova (Germany) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Aenova (Germany) Drug Contaminants Detection and Analysis Product Portfolio
  96. 8.16.5 Aenova (Germany) Recent Developments
  97. 8.17 Sterling Pharma Solutions (UK)
  98. 8.17.1 Sterling Pharma Solutions (UK) Company Information
  99. 8.17.2 Sterling Pharma Solutions (UK) Business Overview
  100. 8.17.3 Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sterling Pharma Solutions (UK) Drug Contaminants Detection and Analysis Product Portfolio
  102. 8.17.5 Sterling Pharma Solutions (UK) Recent Developments
  103. 8.18 Curia (USA)
  104. 8.18.1 Curia (USA) Company Information
  105. 8.18.2 Curia (USA) Business Overview
  106. 8.18.3 Curia (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Curia (USA) Drug Contaminants Detection and Analysis Product Portfolio
  108. 8.18.5 Curia (USA) Recent Developments
  109. 8.19 Ardena (Belgium)
  110. 8.19.1 Ardena (Belgium) Company Information
  111. 8.19.2 Ardena (Belgium) Business Overview
  112. 8.19.3 Ardena (Belgium) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Ardena (Belgium) Drug Contaminants Detection and Analysis Product Portfolio
  114. 8.19.5 Ardena (Belgium) Recent Developments
  115. 8.20 Hovione (Portugal)
  116. 8.20.1 Hovione (Portugal) Company Information
  117. 8.20.2 Hovione (Portugal) Business Overview
  118. 8.20.3 Hovione (Portugal) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Hovione (Portugal) Drug Contaminants Detection and Analysis Product Portfolio
  120. 8.20.5 Hovione (Portugal) Recent Developments
  121. 8.21 Delpharm (France)
  122. 8.21.1 Delpharm (France) Company Information
  123. 8.21.2 Delpharm (France) Business Overview
  124. 8.21.3 Delpharm (France) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Delpharm (France) Drug Contaminants Detection and Analysis Product Portfolio
  126. 8.21.5 Delpharm (France) Recent Developments
  127. 8.22 AGC Biologics (USA)
  128. 8.22.1 AGC Biologics (USA) Company Information
  129. 8.22.2 AGC Biologics (USA) Business Overview
  130. 8.22.3 AGC Biologics (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  131. 8.22.4 AGC Biologics (USA) Drug Contaminants Detection and Analysis Product Portfolio
  132. 8.22.5 AGC Biologics (USA) Recent Developments
  133. 8.23 FUJIFILM Biotechnologies (Japan)
  134. 8.23.1 FUJIFILM Biotechnologies (Japan) Company Information
  135. 8.23.2 FUJIFILM Biotechnologies (Japan) Business Overview
  136. 8.23.3 FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  137. 8.23.4 FUJIFILM Biotechnologies (Japan) Drug Contaminants Detection and Analysis Product Portfolio
  138. 8.23.5 FUJIFILM Biotechnologies (Japan) Recent Developments
  139. 8.24 KBI Biopharma (USA)
  140. 8.24.1 KBI Biopharma (USA) Company Information
  141. 8.24.2 KBI Biopharma (USA) Business Overview
  142. 8.24.3 KBI Biopharma (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  143. 8.24.4 KBI Biopharma (USA) Drug Contaminants Detection and Analysis Product Portfolio
  144. 8.24.5 KBI Biopharma (USA) Recent Developments
  145. 8.25 Rentschler Biopharma (Germany)
  146. 8.25.1 Rentschler Biopharma (Germany) Company Information
  147. 8.25.2 Rentschler Biopharma (Germany) Business Overview
  148. 8.25.3 Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Rentschler Biopharma (Germany) Drug Contaminants Detection and Analysis Product Portfolio
  150. 8.25.5 Rentschler Biopharma (Germany) Recent Developments
  151. 8.26 Ajinomoto Bio-Pharma Services (Japan)
  152. 8.26.1 Ajinomoto Bio-Pharma Services (Japan) Company Information
  153. 8.26.2 Ajinomoto Bio-Pharma Services (Japan) Business Overview
  154. 8.26.3 Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Ajinomoto Bio-Pharma Services (Japan) Drug Contaminants Detection and Analysis Product Portfolio
  156. 8.26.5 Ajinomoto Bio-Pharma Services (Japan) Recent Developments
  157. 8.27 Bora Pharmaceuticals (Taiwan, China)
  158. 8.27.1 Bora Pharmaceuticals (Taiwan, China) Company Information
  159. 8.27.2 Bora Pharmaceuticals (Taiwan, China) Business Overview
  160. 8.27.3 Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Bora Pharmaceuticals (Taiwan, China) Drug Contaminants Detection and Analysis Product Portfolio
  162. 8.27.5 Bora Pharmaceuticals (Taiwan, China) Recent Developments
  163. 8.28 Kindeva (USA)
  164. 8.28.1 Kindeva (USA) Company Information
  165. 8.28.2 Kindeva (USA) Business Overview
  166. 8.28.3 Kindeva (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Kindeva (USA) Drug Contaminants Detection and Analysis Product Portfolio
  168. 8.28.5 Kindeva (USA) Recent Developments
  169. 8.29 CordenPharma (Switzerland)
  170. 8.29.1 CordenPharma (Switzerland) Company Information
  171. 8.29.2 CordenPharma (Switzerland) Business Overview
  172. 8.29.3 CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  173. 8.29.4 CordenPharma (Switzerland) Drug Contaminants Detection and Analysis Product Portfolio
  174. 8.29.5 CordenPharma (Switzerland) Recent Developments
  175. 8.30 RSSL (UK)
  176. 8.30.1 RSSL (UK) Company Information
  177. 8.30.2 RSSL (UK) Business Overview
  178. 8.30.3 RSSL (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  179. 8.30.4 RSSL (UK) Drug Contaminants Detection and Analysis Product Portfolio
  180. 8.30.5 RSSL (UK) Recent Developments
  181. 8.31 Tentamus (Germany)
  182. 8.31.1 Tentamus (Germany) Company Information
  183. 8.31.2 Tentamus (Germany) Business Overview
  184. 8.31.3 Tentamus (Germany) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  185. 8.31.4 Tentamus (Germany) Drug Contaminants Detection and Analysis Product Portfolio
  186. 8.31.5 Tentamus (Germany) Recent Developments
  187. 8.32 Element Materials Technology (UK)
  188. 8.32.1 Element Materials Technology (UK) Company Information
  189. 8.32.2 Element Materials Technology (UK) Business Overview
  190. 8.32.3 Element Materials Technology (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  191. 8.32.4 Element Materials Technology (UK) Drug Contaminants Detection and Analysis Product Portfolio
  192. 8.32.5 Element Materials Technology (UK) Recent Developments
  193. 8.33 Nucro-Technics (Canada)
  194. 8.33.1 Nucro-Technics (Canada) Company Information
  195. 8.33.2 Nucro-Technics (Canada) Business Overview
  196. 8.33.3 Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  197. 8.33.4 Nucro-Technics (Canada) Drug Contaminants Detection and Analysis Product Portfolio
  198. 8.33.5 Nucro-Technics (Canada) Recent Developments
  199. 8.34 ALS (Australia)
  200. 8.34.1 ALS (Australia) Company Information
  201. 8.34.2 ALS (Australia) Business Overview
  202. 8.34.3 ALS (Australia) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  203. 8.34.4 ALS (Australia) Drug Contaminants Detection and Analysis Product Portfolio
  204. 8.34.5 ALS (Australia) Recent Developments
  205. 8.35 Aizant (India)
  206. 8.35.1 Aizant (India) Company Information
  207. 8.35.2 Aizant (India) Business Overview
  208. 8.35.3 Aizant (India) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  209. 8.35.4 Aizant (India) Drug Contaminants Detection and Analysis Product Portfolio
  210. 8.35.5 Aizant (India) Recent Developments
  211. 8.36 Wickham Laboratories (UK)
  212. 8.36.1 Wickham Laboratories (UK) Company Information
  213. 8.36.2 Wickham Laboratories (UK) Business Overview
  214. 8.36.3 Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  215. 8.36.4 Wickham Laboratories (UK) Drug Contaminants Detection and Analysis Product Portfolio
  216. 8.36.5 Wickham Laboratories (UK) Recent Developments
  217. 8.37 Toxikon (USA)
  218. 8.37.1 Toxikon (USA) Company Information
  219. 8.37.2 Toxikon (USA) Business Overview
  220. 8.37.3 Toxikon (USA) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  221. 8.37.4 Toxikon (USA) Drug Contaminants Detection and Analysis Product Portfolio
  222. 8.37.5 Toxikon (USA) Recent Developments
  223. 8.38 Evotec (Germany)
  224. 8.38.1 Evotec (Germany) Company Information
  225. 8.38.2 Evotec (Germany) Business Overview
  226. 8.38.3 Evotec (Germany) Drug Contaminants Detection and Analysis Revenue and Gross Margin (2021-2026)
  227. 8.38.4 Evotec (Germany) Drug Contaminants Detection and Analysis Product Portfolio
  228. 8.38.5 Evotec (Germany) Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst